Search research articles
Contact Us
Filters
Showing results (81-90 of 148) with videos related to
Page
of 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2009
ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays
Klaus H Metzeler, Annika Dufour, Tobias Benthaus, et al.
Molecular Oncology
|
April 23, 2009
The CALM and CALM/AF10 interactor CATS is a marker for proliferation
Leticia Fröhlich Archangelo, Philipp A Greif, Michael Hölzel, et al.
Haematologica
|
June 12, 2025
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance
Christian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, et al.
Blood
|
September 15, 2007
Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia
Vijay P S Rawat, Silvia Thoene, Vegi M Naidu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> Trial
Judith Trotman, Christian Buske, Alessandra Tedeschi, et al.
Blood Advances
|
September 3, 2021
Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study
Christian Buske, Wojciech Jurczak, Juan-Manuel Sancho, et al.
Cell Death & Disease
|
January 8, 2021
SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype
Dario Bongiovanni, Melissa Klug, Olga Lazareva, et al.
Genome Biology
|
November 9, 2018
LaminA/C regulates epigenetic and chromatin architecture changes upon aging of hematopoietic stem cells
Ani Grigoryan, Novella Guidi, Katharina Senger, et al.
Hemasphere
|
September 30, 2021
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial
Mathias Witzens-Harig, Andreas Viardot, Ulrich Keller, et al.
Seminars in Hematology
|
May 25, 2025
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom's Macroglobulinemia
Shayna Sarosiek, Anne-Marie L Becking, Andrew Branagan, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 148) with videos related to
Sort By:
Page
of 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2009
ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays
Klaus H Metzeler, Annika Dufour, Tobias Benthaus, et al.
Molecular Oncology
|
April 23, 2009
The CALM and CALM/AF10 interactor CATS is a marker for proliferation
Leticia Fröhlich Archangelo, Philipp A Greif, Michael Hölzel, et al.
Haematologica
|
June 12, 2025
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance
Christian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, et al.
Blood
|
September 15, 2007
Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia
Vijay P S Rawat, Silvia Thoene, Vegi M Naidu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> Trial
Judith Trotman, Christian Buske, Alessandra Tedeschi, et al.
Blood Advances
|
September 3, 2021
Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study
Christian Buske, Wojciech Jurczak, Juan-Manuel Sancho, et al.
Cell Death & Disease
|
January 8, 2021
SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype
Dario Bongiovanni, Melissa Klug, Olga Lazareva, et al.
Genome Biology
|
November 9, 2018
LaminA/C regulates epigenetic and chromatin architecture changes upon aging of hematopoietic stem cells
Ani Grigoryan, Novella Guidi, Katharina Senger, et al.
Hemasphere
|
September 30, 2021
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial
Mathias Witzens-Harig, Andreas Viardot, Ulrich Keller, et al.
Seminars in Hematology
|
May 25, 2025
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom's Macroglobulinemia
Shayna Sarosiek, Anne-Marie L Becking, Andrew Branagan, et al.
Page
of 15